Figure 1.

Distribution of provider beliefs on the effectiveness of the use of primary human papillomavirus (pHPV) testing, cytology alone, and cotesting on reducing lifetime risk of cervical cancer mortality by age and site. Providers who did not respond to this survey item for each age category were excluded (cytology alone, for patients 21-29 years old, n = 1 and for patients 30-65 years old, n = 0; cotesting, for patients 21-29 years old, n = 4 and for patients 30-65 years old, n = 4; and primary HPV testing, for patients 21-29 years old, n = 4 and for patients 30-65 years old, n = 4). The χ²P values at the lower right corner of each section compare provider responses across screening modalities (α = .05). KPWA = Kaiser Permanente Washington; MGB = Mass General Brigham; PH/UTSW = Parkland Health/University of Texas Southwestern Medical Center.